We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

AVI BioPharma Initiates Dosing in Phase 2 Study of Eteplirsen in Duchenne Muscular Dystrophy Patients

News   Aug 18, 2011

 
AVI BioPharma Initiates Dosing in Phase 2 Study of Eteplirsen in Duchenne Muscular Dystrophy Patients
 
 
 

RELATED ARTICLES

Wrinkles on the Skin of a Worm May Hold the Key to a Longer, Healthier Life for Humans

News

Working with Caenorhabditis elegans, a transparent nematode found in soil, researchers were the first to find that the nervous system controls the tiny worm's cuticle, a skin-like exterior barrier, in response to bacterial infections.

READ MORE

Safety and Efficacy Results From CRISPR/Cas9 Human Clinical Trials Are Positive

News

CRISPR Therapeutics and Vertex Pharmaceuticals have announced their interim safety and efficacy results from the CTX001 CRISPR/Cas9 gene-editing human clinical trials - and they're promising.

READ MORE

Collaboration Aims To Improve Efficacy of Lung Cancer Drug

News

The University of Barcelona and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug used to treat lung cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE